Eikon Therapeutics’ Post

Given the state of capital markets and challenges faced by biotech companies to raise funds, how is this impacting the kinds of deals being struck? This, and many other questions will be addressed by speakers from Roche, Astellas Pharma, Evotec, Triumvira Immunologics, Inc., Takeda and Affini-T Therapeutics during our upcoming webinar on September 14. Register now: https://ow.ly/2Fr350PFWEf #biotech #pharma #partnerships #webinar

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series. LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various http://ow.ly/1536104SxXy #UNCY #unicycive #pharma $UNCY

Phase 2 & 3 Data Readouts Left This Quarter.. Here's a few of the biggest to watch 👇 UroGen Pharma - Phase 3 data from ENVISION study Viking Therapeutics, Inc. - Phase 2b data from VOYAGE study. Lipocine Inc. - Topline results from pivotal PK study. See table below for ph 2 & 3 readouts this quarter. --- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your BD/investing activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series. LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various http://ow.ly/1536104SxXy #UNCY #unicycive #pharma $UNCY

In part two of our discussion with Outsourced Pharma's Louis_Garguilo, Lineage Cell Therapeutics CEO Brian Culley discusses the importance of internal oversight for the manufacturing of cells. Learn more here: https://bit.ly/3SPIsca #ReplaceAndRestore #celltransplant

https://lnkd.in/e3pKeuvW Sheppard Mullin Advises Unicycive Therapeutics in $50 Million Private Placement The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $50 million private placement. The financing is led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing healthcare institutional investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital and Walleye Capital. Sheppard Mullin previously advised Unicycive in its $130 million private placement in March 2023. #biotech #clinicaltrials #financing #corporatelaw #lifesciences #pharmaceutical #patentlaw #patents #investors #privateplacement #therapeutics #bestinclass #clinicaldevelopment #shares #preferredequity #kidneydisease #dialysis #treatment #productlaunch #capitalraising #securitieslaw #nda #fda #drugdevelopment #phosphate #patentprotection #nce #chemical #acute #kidneyhealth #fdacompliance #nanoparticles #pharmaceutical #therapies #innovation #sec

Great article about Vincerx and our founders! Our molecule concepts are game changers and can become breakthrough therapies in the oncology field. Everyday my work supports our clinical trials in one way or another, and I’m thankful to be able to play a role in the fight against cancer. #cancertreatment #cancerresearch #oncology #clinicaltrials #adc

#WhySwitzerland for biotech & pharma? 💡 Anne Marie de Jonge-Schuermans, Board Member of the 🇨🇭 Swiss Biotech Association and Global Head of Biologics & Injectables Operations at Sandoz, discusses the Swiss biopharma ecosystem and the business and career opportunities with Medicine Maker. 🚀 Read about it in this article: https://loom.ly/D6U5z3k The Medicine Maker, Swiss Biotech Association, Sandoz

💡 𝑯𝒐𝒘 𝒄𝒂𝒏 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒐𝒓𝒔 𝒂𝒕𝒕𝒓𝒂𝒄𝒕 𝒇𝒖𝒏𝒅𝒊𝒏𝒈 𝒘𝒉𝒆𝒏 𝒘𝒐𝒓𝒌𝒊𝒏𝒈 𝒊𝒏 𝒂 𝒏𝒐𝒗𝒆𝒍 𝒇𝒊𝒆𝒍𝒅? Especially now when the investment landscape is so tough!     While working on our RNA therapeutics whitepaper, Guillermo Tramontin and I posed this question to Alessandro Toniolo, a seasoned CEO at Resalis Therapeutics and renowned for his leadership of biotech and pharmaceutical firms.      His answer: “A strong team with a clear strategy, consistent results, and a clear plan to address the inevitable issues that emerge when proceeding in an unexplored field.”  You can find plenty more straight-to-the-point, actionable insights from our conversation with Alessandro here https://lnkd.in/e8WKZVTg.      #rnatherapeutics #biotech #pharma #venturecapital #clinicaldevelopment 

What are #digitaltherapeutics bringing that's better or different from traditional treatment approaches?   Dr Pamela Walker and Dr Jessica Shull PhD of Vicore Pharma AB caught up recently to discuss the evolution of the role of digital therapeutics, recent innovations in the space and what impact they may have over the next five years.   Listen to an extract of their conversation below and check out the full episode here: https://lnkd.in/eCk9JwqJ #lifesciences #pharma #pharmainnovation